Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC, doing business as Merck, is a for-profit pharmaceutical manufacturer headquartered in Rahway, New Jersey, that supplies vaccines, specialty therapeutics, and medical countermeasures to federal healthcare and defense agencies as a prime contractor on full-and-open (non-set-aside) federal supply schedules and indefinite delivery vehicles. Merck operates as a subsidiary of parent company Schering Plough Corporation and competes predominantly without SBA certifications across 895 recent awards with combined potential value of $63.19 billion.

Merck's federal footprint centers on vaccine and pharmaceutical procurement under three primary capability buckets: pediatric vaccines for the CDC's Vaccines for Children program, adult vaccines for federal immunization initiatives, and specialty oncology and pulmonary hypertension therapeutics for the Veterans Health Administration. The company holds a $4.48 billion multiple-award indefinite delivery contract with CDC Pittsburgh for pediatric vaccines (Vaccines for Children program, April 2026 through March 2027), a $66.01 million adult vaccines IDIQ (July 2025 through June 2026), and a $5.84 billion Federal Supply Schedule contract with the Department of Veterans Affairs for pharmaceuticals and drugs (FSS-61-IB, June 2025 through May 2030). Representative delivery orders under FSS-61-IB include WINREVAIR (sotatercept-csrk) for pulmonary hypertension at $21.4 million (VA VISN 9, September 2026), Welireg (belzutifan) for renal cell carcinoma at $44.1 million (VA VISN 20, February 2025), and routine pharmaceutical replenishment across multiple VA regional networks at $10,500 to $96,200 per order. Merck also received a $173.8 million sole-source definitive contract from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response for ERVEBO Zaire ebolavirus vaccine procurement and strategic national stockpile storage (September 2024 through September 2034), along with a $9.5 million single-award CDC Pittsburgh contract for vaccine stockpile storage and rotation services (September 2026 through September 2031).

Customer concentration is extreme and anchored by vaccine and immunization programs. CDC Pittsburgh accounts for 33 awards totaling $43.38 billion combined potential value (69% of all Merck dollars), driven by the Vaccines for Children program IDIQ alone at $4.48 billion. The Department of Veterans Affairs (via multiple Veterans Integrated Service Networks and the National Acquisition Center) represents 93 awards totaling $15.28 billion, dominated by the $5.84 billion FSS-61-IB vehicle. The Defense Logistics Agency placed 308 awards (34% of award count) but represents a small-dollar subset reflecting medical supply distribution and routine replenishment activity. The top five customers by dollar value account for 94% of combined potential value. When ranked by award count, DLA leads (308 awards) followed by HHS Office of the Assistant Secretary for Administration (144 awards), but these rankings diverge sharply from potential-value concentration—DLA's numerous small orders contrast with CDC and VA's mega-vehicle ceilings.

Activity has accelerated in recent years, from 15 awards in 2022 to 34 in 2025 and 20 in 2026 year-to-date, reflecting sustained federal demand for vaccines and specialty therapeutics. Two awards face ultimate completion within the next twenty-four months with combined potential value of $291.4 million, creating modest recompete exposure. Merck's top parent vehicles include the VA's FSS-61-IB (134 delivery orders, $94 million combined potential value), Federal Supply Schedule V797P5893X (209 task orders, $10.6 million), and Basic Ordering Agreement V797P5230J (20 task orders). The company also holds an Other Transaction Agreement for Prototype with the Joint Program Executive Office for Chemical and Biological Defense valued at $39.1 million (March 2025) for development of molnupiravir as an oral therapeutic for Venezuelan Equine Encephalitis Virus, and a $72.5 million Blanket Purchase Agreement with the National Acquisition Center for Welireg (July 2025 through July 2027).

SCI-reported federal service contract activity is minimal—$5 million invoiced across FY2022–FY2025 under eight prime records, reflecting roughly 0.1 FTEs annually—indicating that Merck's federal engagement is dominated by product procurement (vaccines and pharmaceuticals) rather than service delivery. This narrow SCI footprint is consistent with Merck's mission as a goods manufacturer rather than a services contractor. Government-paid rates on the limited SCI-reportable service work run median $8,880/hr with senior labor pricing through approximately $10,800/hr, but these figures apply to a trivial portion of Merck's federal footprint. Merck operates as a prime contractor across all 895 awards; sub-award activity is negligible (two grant sub-awards listed, zero contract subs), reflecting Merck's role as a direct supplier of manufactured products rather than a coordinator of subcontract delivery teams. Named subsidiaries include Biomark LLC and Cidara Therapeutics Inc., though the source does not detail their federal activity.

Merck's competitive posture is full-and-open and non-set-aside across its entire federal portfolio. The company does not hold 8(a), HUBZone, SDVOSB, WOSB, or other SBA certifications and does not compete under set-aside vehicles. Its federal strategy anchors on established manufacturer status, FDA-licensed product supply, and incumbency on high-value CDC vaccine and VA pharmaceutical IDIQs—relationships that foreclose meaningful competitive exposure to small business set-asides or emerging vendors. Merck's federal market position is reinforced by sole-source or near-sole-source procurement for specialized products (ERVEBO ebolavirus vaccine, strategic national stockpile services, molnupiravir antivirals) where manufacturing capability or intellectual property creates competitive moats.